Treatment for ALL (UKALLXI) 1 includes: | Potential late effects include: |
---|---|
Anthracyclines (daunorubicin (180 mg/m2) | Cardiomyopathy—risk increases with increasing dose |
Steroids | Reduced bone density |
Obesity | |
High dose methotrexate | Reduced bone density |
Etoposide | Secondary leukaemia |
At relapse chemo included: | |
Anthracyclines (additional 200 mg/m2 epirubicin) | Increased risk of cardiomyopathy |
Bone marrow conditioning | Potential late effects |
---|---|
Total body irradiation (TBI) | Second malignancy (particularly skin and thyroid) |
Thyroid nodules | |
Cataracts | |
Endocrine dysfunction (see table 2) | |
Gonadal failure | |
Sicca syndrome | |
Restrictive lung defect | |
Cardiac dysfunction | |
Cyclophosphamide | Potentiates cardiac effects of anthracyclines |
Pulmonary toxicity | |
Gonadal dysfunction |